Fab

Fab Biopharma is a biotechnology company focused on developing novel therapeutics for autoimmune diseases that disproportionately affect women, such as Sjögren's Syndrome and Systemic Lupus Erythematosus (SLE). The company utilizes a proprietary platform to engineer bispecific soluble receptor Fc fusion proteins that simultaneously target T and B cell-activating cytokines, including BAFF and APRIL. By intercepting these extracellular ligands, Fab Biopharma aims to restore immune homeostasis while avoiding the broad immunosuppression and toxicity associated with traditional treatments. Led by a team of industry veterans with experience in blockbuster biologics like Enbrel and Benlysta, the company is advancing its pipeline toward clinical trials with a focus on medical equity and female-centered research.